Insight Genetics, Vanderbilt-Ingram Aim to ID Novel Rx Response Markers in TNBC | GenomeWeb

NEW YORK (GenomeWeb News) – Insight Genetics is working with Vanderbilt-Ingram Cancer Center to identify genetic markers associated with treatment response for triple-negative breast cancer patients.

Triple-negative breast cancer patients – women who don't express genes for estrogen receptor, progesterone receptor, and HER2 – have limited treatment options, and they are at greater risk of relapse than women with other types of breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.